Somewhat Positive News Coverage Somewhat Unlikely to Impact Opiant Pharmaceuticals (OPNT) Stock Price

News coverage about Opiant Pharmaceuticals (NASDAQ:OPNT) has trended somewhat positive recently, Accern reports. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Opiant Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news articles about the technology company an impact score of 45.9581978319695 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media stories that may have impacted Accern Sentiment’s scoring:

Separately, ValuEngine raised shares of Opiant Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 12th.

Shares of Opiant Pharmaceuticals (NASDAQ OPNT) opened at 35.70 on Wednesday. Opiant Pharmaceuticals has a 12 month low of $5.00 and a 12 month high of $51.90. The stock has a market cap of $72.33 million, a PE ratio of 13.43 and a beta of -0.75. The stock has a 50 day moving average of $27.21 and a 200 day moving average of $12.29.

TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Opiant Pharmaceuticals (OPNT) Stock Price” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

Receive News & Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply